-

04:42:25 AM

IONS Stock News

IONS - Ionis Pharmaceuticals Inc

06/08/23 1:09 AM

Nasdaq : IONS

Ionis prices private placement of convertible senior notes

Ionis Pharmaceuticals, Inc. announced today the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 in a private placement to qualified institutional buyers pursuant to Rule 144 A under the Securities Act of 1933, as amended. Ionis also granted the initial purchasers of...

RHEA-AI

neutral

06/06/23 4:01 PM

Nasdaq : IONS

Ionis announces proposed private placement of convertible notes

Ionis Pharmaceuticals, Inc. announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 in a private placement to qualified institutional buyers pursuant to Rule 144 A under the Securities Act of 1933, as...

RHEA-AI

neutral

06/01/23 7:05 AM

Nasdaq : IONS

Ionis announces positive donidalorsen late-stage clinical progress in HAE

Ionis Pharmaceuticals, Inc. today announced positive clinical progress with...

RHEA-AI

neutral

05/10/23 7:05 AM

Nasdaq : IONS

conferences

Ionis to host 2023 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals, Inc. today announced that management will conduct its 2023 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 1, 2023.. The agenda for the event is as follows:. 5:00 p.m.– 5:15 p.m. ET– Virtual Annual Meeting of Stockholders All stockholders of record...

RHEA-AI

neutral

05/09/23 7:05 AM

Nasdaq : IONS

conferences

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. today announced that management will participate in fireside chats at the following investor conferences:. RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 Goldman Sachs 44 th Annual Global Healthcare Conference on Monday, June 12, 2023. A live webcast of the...

RHEA-AI

neutral

05/03/23 7:00 AM

Nasdaq : IONS

earnings

Ionis reports first quarter 2023 financial results

Ionis Pharmaceuticals, Inc., today reported financial results for the first quarter of 2023. Revenue for the first quarter of 2023 was in line with expectations and included revenue from numerous diverse sources Operating expenses increased in the first quarter of...

RHEA-AI

neutral

04/25/23 7:10 PM

Nasdaq : IONS

fda approval

FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS

Ionis Pharmaceuticals, Inc. today announced that its partner Biogen has received U.S. Food and Drug Administration approval of QALSODY™ 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis in adults who have a mutation in the superoxide dismutase 1 gene. This indication is approved under accelerated approval based on a reduction in...

RHEA-AI

neutral

04/24/23 7:00 AM

Nasdaq : IONS

clinical trial

Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks

NEURO-TTRansform study met all co-primary and secondary endpoints Positive results to be presented today at AAN 2023 demonstrate eplontersen efficacy, safety and administration profile may provide an important new treatment option in this fatal disease with significant unmet need Ionis to host

RHEA-AI

positive

04/20/23 7:05 AM

Nasdaq : IONS

earnings

Ionis to hold first quarter 2023 financial results webcast

Ionis Pharmaceuticals, Inc. announced today that it will host a live webcast on Wednesday, May 3 rd at 11:30 a.m. Eastern Time to discuss its first quarter 2023 financial results. The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. About Ionis Pharmaceuticals, Inc. For more than 30 years, Ionis has been...

RHEA-AI

neutral

03/29/23 8:45 AM

Nasdaq : IONS

New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease

Ionis Pharmaceuticals, Inc. today reported that its partner Biogen presented new Phase 1 b clinical data showing that IONIS-MAPT Rx reduced soluble tau protein in cerebrospinal fluid in a dose-dependent and sustained manner in patients with early-stage Alzheimer's disease. The results were presented today at the International Conference on...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

IONS Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.ionispharma.com
CeoBrett Monia
Security nameIonis Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees757
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2855 Gazelle Ct
StateCalifornia
CityCarlsbad
Zip92010-6670
CountryUS
Phone17609319200

About Ionis Pharmaceuticals Inc

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies.